OraSure files 510(k) for drugs-of-abuse diagnostic:
This article was originally published in Clinica
Executive Summary
OraSure Technologies has filed a 510(k) application with the US FDA for permission to market its point-of-care oral fluid drugs-of-abuse diagnostic system. The UPlink reader has been submitted to the agency together with assays for detecting cocaine, opiates and amphetamines. The Bethlehem, Pennsylvania company plans to submit two additional tests - for marijuana and phencyclidine - within the next two months. The UPlink system is also being developed for gastrointestinal and respiratory infectious disease testing under an agreement with Meridian Diagnostics.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.